Factors associated with poor medication adherence during COVID-19 pandemic among hypertensive patients visiting public hospitals in Eastern Ethiopia: a cross-sectional study

Lemesa Abdisa, Addisu Alemu, Helina Heluf, Addisu Sertsu, Yadeta Dessie, Belay Negash, Galana Mamo Ayana, Shiferaw Letta

ABSTRACT

Objective This study aimed to assess factors associated with poor medication adherence during the COVID-19 pandemic among hypertensive patients visiting public hospitals in Eastern Ethiopia.

Setting Hospital-based cross-sectional study was conducted in Harari regional state and Dire Dawa Administration from 1 January to 30 February 2022. Both settings are found in Eastern Ethiopia.

Participants A total of 402 adult hypertensive patients who visited the chronic diseases clinic for follow-up were included in the study.

Main outcome measures The main outcome measure was poor medication adherence during the COVID-19 pandemic.

Results The level of poor antihypertensive medication adherence was 63% (95% CI 48.1 to 67.9). Patients who had no formal education (adjusted OR (AOR)=1.56, 95% CI 1.03 to 4.30), existing comorbid conditions (AOR=1.98, 95% CI 1.34 to 4.73), poor knowledge about hypertension (HTN) and its treatment (AOR=2.67, 95% CI 1.45 to 4.35), self-funded medication cost (AOR=2.05, 95% CI 1.34 to 4.73), poor patient–physician relationship (AOR=1.22, 95% CI 1.02 to 4.34) and unavailability of medication (AOR=5.05, 95% CI 2.78 to 12.04) showed significant association with poor medication adherence during the pandemic of COVID-19.

Conclusion The level of poor antihypertensive medication adherence was high in this study. No formal education, comorbidity, self-funded medication cost, poor knowledge about HTN and its treatment, poor patient–physician relationship, and unavailability of medication during the COVID-19 pandemic were factors significantly associated with poor adherence to antihypertensive medication. All stakeholders should take into account and create strategies to reduce the impact of the COVID-19 pandemic on medication adherence of chronic diseases.

INTRODUCTION

Hypertension (HTN) is affecting one billion people globally and causes around 10 million deaths and 2 million disabilities annually. The burden of high blood pressure (BP) is significantly increasing in sub-Saharan Africa (SSA) over the past two to three decades. In SSA, 80 million people were living with HTN in 2000, projected to be 150 million by 2025. Even though, no countrywide study in Ethiopia the result of systematic review and meta-analysis showed that the prevalence of HTN was 19.6%.

In a broader sense, HTN management requires a multifactorial approach which is classified into two main categories: pharmacological therapy and lifestyle modifications. Lifestyle modification includes a healthy diet, being physically active, non-smoking and weight management. Antihypertensive medication adherence is another important component of HTN management which significantly decreases hospitalisations rates and lower medical care costs.

Many studies have suggested that high adherence to antihypertensive medication improves clinical outcomes and reduces the risk of cardiovascular diseases. However, the impact of COVID-19 on antihypertensive drug adherence in low-income and
middle-income countries doubled the burden of non-communicable diseases including HTN. The health systems of all countries faced a huge challenge related to prevention, reducing and overcoming the effect of the spread of COVID-19, providing timely medical care and adequate medical therapy, and regulating the risk of unavailability of drugs.

During this period, pharmaceutical companies are concentrated on battling COVID-19. Moreover, inadequate manufacturing capabilities and paying for the cost of the medication were the key problems.

In Ethiopia, inadequate supply to meet the increased demand created by COVID-19 made many patients unable to afford the cost of their medications. Even though antihypertensive drug adherence affects the HTN outcome, accessibility and affordability of the medication have negatively affected medication adherence during the period of the pandemic. Therefore, this study aimed to assess factors associated with poor medication adherence during the COVID-19 pandemic among hypertensive patients visiting public hospitals in Eastern Ethiopia.

MATERIALS AND METHODS
Study area, period and design
A hospital-based cross-sectional study was conducted from January 1 to February 30, 2022 at public hospitals found in Harari regional state and Dire Dawa Administration, Eastern Ethiopia. Harari regional state is one of the eleven regional states in Ethiopia. Harar is the capital city of the Harari region, and it is found 526 km away from Addis Ababa in the Eastern direction. The total population of the town was projected to be 263 455 of which 132 294 are women in 2022. Harari region has two public hospitals: Hiwot Fana Compressive Specialised University Hospital (HCFSUH) and Jugal General Hospital (JH). Dire Dawa Administration is one of the administration of the Federal Democratic Republic of Ethiopia. Dire Dawa administration is found 515 km away from Addis Ababa in the Eastern direction. The estimated total population of the Dire Dawa Administration was 629 855, of whom 316 861 are women in 2022. Dire Dawa Administration has two public hospitals, namely, Dilchora Referral Hospital (DRH) and Sabian General Hospital (SGH).

Patient and public involvement
There was no patient or public involvement in this research.

Study participants and eligibility criteria
The first COVID-19 case was confirmed on 13 March 2020 in Ethiopia. Until 1 February 2022, there were 439 892 COVID-19 cases. During the study period (January–February 2022), there were 48 332 COVID-19 new cases reported in Ethiopia. All adult (≥ 18 years old) hypertensive patients on follow-up clinic and who were on antihypertensive treatment for at least months before the data collection period were included in this study. However, patients with severe illnesses who could not respond to the interview and those who had cognitive problem were excluded.

Sampling and sampling procedure
A single population proportion formula was used to calculate the sample size. The assumptions considered were 95% confidence level, 5% margin of error and 40% prevalence of poor medication adherence. By adding 10% non-response rate, the final sample size became 406. This research was conducted at four public hospitals in the Harari regional state and Dire Dawa Administration in Eastern Ethiopia. The expected number of patients coming to the hypertensive follow-up clinic was approximated from the previous quarterly report. Then the total number of hypertensive patients approximated for the 2-month (data collection) period was 1868. Then, the calculated sample size was proportionally allocated to each hospital based on the respective number of patients. The study participants were then selected using systematic random sampling (k=1868/406=4.6≈4). The first study participant was selected by using the lottery method.

Study variables and measurements
Dependent variable
The dependent variable was poor medication adherence.

Independent variable
Sociodemographic related factors were sex, age, marital status, religion, educational status, occupation and place of residence. Clinical and patient-related factors were BP control status, presence of comorbidity, medication cost coverage, duration of treatment, number of medication, medication side effect and patient–physician relationship, social support, knowledge about HTN and its treatment, and effect of the COVID-19 pandemic (unavailability of medication and unaffordability or increased price).

Data collection tool and procedure
Data were collected through face-to-face interviews and record reviews using pretested and structured questionnaires. Medication adherence was measured by a modified version of the Medication Adherence Rating Scale (MARS), and its Cronbach’s alpha was 0.91. Hypertension Knowledge-Level Scale (HKLS) with a Cronbach’s alpha of 0.93 was used to measure respondents’ knowledge about HTN and its treatment. The patient–physician relationship was assessed by the patient–physician Relationship Questionnaire and had a Cronbach alpha of 0.93. Duke Social Support and Stress Scale with a Cronbach’s alpha was 0.88. All
the aforementioned standard measurement scales had an acceptable level of internal consistency. The questionnaire was originally developed in English and translated into the local language (Afaan Oromo, Amharic and Af-Somali) for data collection based on the patient’s language preference (online supplemental file 1).

Operational definition

**BP control status**
BP control status of patients was classified into two categories based on the average of the three consecutive BP measurements. Uncontrolled BP referred to the BP measurement of ≥140/90 and ≥130/80 mm Hg for hypertensive patients with diabetic mellitus and chronic kidney diseases otherwise it was controlled BP.

**Comorbidity**
Existence of one or more chronic disease or conditions other than HTN.

**Good knowledge**
Knowledge of HTN and its treatment was categorized as good and poor based on median value. Patients scored above or equal to the median of the HK-LS was considered to have good knowledge.

**Level of social support**
Patients’ social support was assessed by Duke’s social support and stress scale based on mean value. The level of social support were considered as good social support if the patient scored above or equal to the mean value of the scale, otherwise it was poor social support.17

**Medication adherence**
Medication adherence was assessed by a validated self-report questionnaire (a modified version of the MARS) originally developed by Thompson et al.14 The MARS contains 10 items with ‘Yes’ or ‘No’ responses. Then ‘No’ was coded as 1, and ‘Yes’ was coded as 0. Patients who correctly answered 8 out of the 10 questions were good adherents unless and otherwise they were poor adherents.

**Patient–physician relationship**
The patient–physician relationship was assessed by nine items of the PDRQ with ‘Yes’ or ‘No’ responses. When patients responded to ≥7 of questions, it was considered a good patient–physician relationship unless and otherwise, it was considered as a poor patient–physician relationship.16

**Data collection procedure and quality control**
The questionnaire was first prepared in English and then translated to the local languages by language experts (Afaan Oromo, Amharic and Af-Somali) and then translated back into English to ensure consistency. The data collectors and supervisors were trained on data collection tools and procedures for 2 days before actual data collection. Moreover, the pretest was conducted among 5% (20) of the total sample at Bisidimo General Hospital.

During the pretest, the applicability of the instruments was checked and feedback was incorporated into the final tool to improve the quality. Continuous follow-up and supervision were done by the supervisor and the principal investigator throughout the data collection period.

**Data processing and analysis**
For statistical analysis, the data were entered into EpiData V.3.1 and exported to SPSS V.25. There were both descriptive and analytical procedures were used. The results of the study were reported in the form of a mean, median, standard deviation, and presented in table, and figure. Researchers used logistic regression analysis models to assess the factors associated with poor medication adherence. For the multivariable logistic regression analysis, variables with a p-value of less than 0.25 in bivriable logistic regression analysis were included. The Hosmer-Lemeshow goodness-of-fit test was performed to assess model adequacy, and adjusted odds ratio (AOR) with 95% confidence level were determined. A statistical significance was declared at a p-value of <0.05. There was no collinearity and multicollinearity among the variables.
from 0 to 22. We used the mean score (13±2.34) as the cut-off point. Of the study participants, 225 (56%) had good knowledge about HTN and its treatment, whereas 177 (44%) had poor knowledge.

**Effect of the COVID-19 pandemic on hypertensive patients**

Among study participants, 245 (61%) reported that the COVID-19 pandemic posed a negative effect on the availability of medications, and 217 (54%) of the study participants reported that antihypertensive medication price was increased or unaffordable due to the COVID-19 pandemic. Out of 402 study participants, 269 (67%) reported that the COVID-19 pandemic disturbed HTN follow-up visits (figure 1).

**Level of medication adherence of study participants**

In this study, the level of poor antihypertensive medication adherence was 63% (95% CI 58.1% to 67.9%) (figure 2).

---

**Table 1** Sociodemographic characteristics of hypertensive patients visiting public health hospitals in Eastern Ethiopia during the COVID-19 pandemic, 2022 (n=402)

| Variable               | Frequency | Per cent (%) |
|------------------------|-----------|--------------|
| Sex                    |           |              |
| Male                   | 210       | 52.2         |
| Female                 | 192       | 47.8         |
| Age (years)            |           |              |
| <60                    | 284       | 70.6         |
| ≥60                    | 118       | 29.4         |
| Marital status         |           |              |
| Single                 | 22        | 5.5          |
| Married                | 230       | 57.2         |
| Divorced               | 94        | 23.4         |
| Widowed                | 56        | 13.9         |
| Religion               |           |              |
| Muslim                 | 154       | 38.3         |
| Orthodox               | 139       | 34.6         |
| Protestant             | 90        | 22.4         |
| Others*                | 19        | 4.7          |
| Educational Level      |           |              |
| No formal education    | 90        | 22.4         |
| Primary education      | 87        | 21.6         |
| Secondary education    | 155       | 38.6         |
| College and above      | 70        | 17.4         |
| Occupation             |           |              |
| Farmer                 | 80        | 19.9         |
| Civil servant          | 136       | 33.8         |
| Merchant               | 116       | 28.9         |
| Housewife              | 52        | 12.9         |
| Other†                 | 18        | 4.5          |
| Place of residence     |           |              |
| Urban                  | 237       | 59           |
| Rural                  | 165       | 41           |

*Others: Catholic, Waqefata.
†Daily labour, retired, student and self-employed.

**Table 2** Clinical and medication-related factors of hypertensive patients visiting public health hospitals in Eastern Ethiopia during the COVID-19 pandemic, 2022 (n=402)

| Variables                        | Frequency | Per cent (%) |
|----------------------------------|-----------|--------------|
| Blood pressure control status    |           |              |
| Controlled                       | 226       | 56.2         |
| Uncontrolled                     | 176       | 43.8         |
| Presence of comorbidity          |           |              |
| Yes                              | 141       | 35.1         |
| No                               | 261       | 64.9         |
| Medication cost coverage         |           |              |
| Health insurance                 | 261       | 64.9         |
| Self-funded                      | 94        | 23.4         |
| Free of charge                   | 47        | 11.7         |
| Duration of treatment (years)    |           |              |
| <5                               | 201       | 50           |
| 5–10                             | 140       | 34.8         |
| >10                              | 61        | 15.2         |
| Number of medications            |           |              |
| Monotherapy                      | 154       | 38.3         |
| Dual therapy                     | 156       | 38.8         |
| Triple therapy & +               | 92        | 22.9         |
| Medication side effect           |           |              |
| Yes                              | 181       | 45           |
| No                               | 221       | 55           |
| Patient–physician relationship   |           |              |
| Good                             | 350       | 87.1         |
| Poor                             | 52        | 12.9         |
Factors associated with poor medication adherence among patients with HTN

The association of dependent and independent variables was investigated using a logistic regression model. From the final multivariable binary logistic regression model educational level, comorbidity, medication cost coverage, knowledge about HTN and treatment, patient–doctor relationship and unavailability of medication due to the COVID-19 pandemic were found to be statistically significant predictors of poor medication adherence.

The results of the current study shows that hypertensive patients who had no formal education were 1.56 times more likely to be poorly adherent to antihypertensive medication than those who had formal education (AOR=1.56, 95% CI 1.03 to 4.30). Hypertensive patients with comorbid conditions were 1.98 times more likely to be poorly adherent to antihypertensive medication as compared with patients without comorbidity (AOR=1.98, 95% CI 1.35 to 4.35). The odds of having poor adherence were two times higher among patients who could afford the cost of medications by self-sponsorship than those who could afford the cost of medications by health insurance or free of charge (AOR=2.05, 95% CI 1.34 to 4.73). Patients with poor knowledge about HTN and its treatment were 2.67 times more likely to be poorly adherent to antihypertensive medication than those who had good knowledge about HTN and treatment (AOR=2.67, 95% CI 1.45 to 3.99). Patients who had a poor patient–physician relationship were 1.22 times more likely to have poor adherence to antihypertensive medication than those who had a good patient–physician relationship (AOR=1.22, 95% CI 1.02 to 4.34). Patients who faced the unavailability of medication during the COVID-19 pandemic were five times more likely to be poorly adherent to antihypertensive medication than those not faced with unavailability of medication (AOR=5.05, 95% CI 2.78 to 12.04) (table 3).

### DISCUSSION

This study assessed factors associated with poor medication adherence during the COVID-19 pandemic among hypertensive patients visiting public hospitals in Eastern Ethiopia. The results of this study revealed that 63% of the patients on follow-up had poor medication adherence, indicating the existence of serious problems that affect both the patients and the healthcare system service delivery. A variety of factors were likely to affect medication adherence. Educational status, comorbidity, self-funded medication cost coverage, poor knowledge about HTN and treatment, poor patient–physician relationship and unavailability of medication during the COVID-19 pandemic were significantly associated with poor adherence to antihypertensive medication. This finding was consistent with a study conducted in Kenya (66.7%).

The finding of this study was higher than those of studies conducted in Egypt (53.88%), Lima, Peru (57.4%); Hong Kong (55.9%); Dessie, Northeastern Ethiopia (48.1%); Jimma, Southwest Ethiopia (38.2%); Northwest Ethiopia (32.8%); Addis Ababa, Ethiopia (33.2%); Asella, Ethiopia (16.5%); Mian-Teferi, Ethiopia (47.06%); and Shashemene, Ethiopia (36.5%).

On the contrary, this finding was relatively lower than those of studies conducted in China (72.54%); Addis Ababa, Ethiopia (72%); and Nedjo, West Ethiopia (68.6%).

In this study, poor adherence to antihypertensive medication was higher among patients who had no formal education, which was in line with other studies conducted in Nedjo, West Ethiopia; Jimma town and southwest Ethiopia. This might be because patients who had formal education should have better knowledge about HTN and its treatment. This increases antihypertensive medication adherence. To improve antihypertensive medication adherence, adherence among patients who had no formal education supplementing oral health education and advice on prescribed drugs is a fundamental component.

Comorbidity showed association with poor medication adherence. This finding also agrees with studies done in Ethiopia and Hong Kong that showed comorbidity conditions as a factor in tackling adherence. This might be because patients with comorbidity commonly suffered from higher pill burden, drug-drug interaction and medication side effects. All of this might cause the patient to miss antihypertensive drugs.

Self-sponsorship or funding for medication cost was a predictor of poor medication adherence. This finding was consistent with other studies conducted in Shanghai and Northwest Ethiopia. This might be due to those self-sponsored/funded patients do not consistently afford to buy their medication while its cost increases. This implies that the need for government and other stakeholders’ commitment towards increasing the awareness acceptance about community-based health insurance.

Poor knowledge about HTN and its treatment showed association with poor adherence to antihypertensive medication. This finding was supported by some studies done...
in Nigeria, Congo, Hawassa, South Ethiopia, Debre Tabor, Northern Ethiopia and Addis Ababa, Ethiopia. Lack of good knowledge about the nature of the disease and importance its treatment might affect the patients’ motivation. Less motivation influence adherence to health care professional instaction and might leads to miss the doses of thier medication.

The poor patient–physician relationship was associated with poor medication adherence. This finding was similar to studies conducted in Shanghai, Southwest Nigeria

### Table 3 Factors associated with poor medication adherence among hypertensive patients visiting public health hospitals in Eastern Ethiopia during the COVID-19 pandemic, 2022 (n=402)

| Variable                        | Medication adherence |   |   |   |   |
|---------------------------------|----------------------|---|---|---|---|
|                                 | Poor (%)             | Good (%) | COR (95% CI) | AOR (95% CI) |   |
| Sex                             | Male                 | 154 (73.3) | 56 (26.7) | 2.58 (1.27 to 5.12) | 1.46 (0.97 to 3.57) |
|                                 | Female               | 99 (51.6)  | 93 (48.4) | 1              | 1 |
| Age                             | <60                  | 196 (69)   | 88 (31)   | 2.38 (1.23 to 4.02) | 1.24 (0.86 to 2.68) |
|                                 | ≥60                  | 57 (48.3)  | 61 (51.7) | 1              | 1 |
| Educational level               | No formal education  | 66 (73.3)  | 24 (26.7) | 1.84 (1.54 to 4.62)* | 1.56 (1.03 to 4.30)* |
|                                 | Formal education     | 187 (60)   | 125 (40)  | 1              | 1 |
| Residence                       | Rural                | 120 (72.7) | 45 (27.3) | 2.09 (1.55 to 5.50) | 1.86 (0.98 to 3.53) |
|                                 | Urban                | 133 (56.1) | 104 (43.9) | 1              | 1 |
| Comorbidity                     | Yes                  | 108 (76.6) | 33 (23.4) | 2.62 (1.64 to 6.67)** | 1.98 (1.35 to 4.35)** |
|                                 | No                   | 145 (55.6) | 116 (44.4) | 1              | 1 |
| Medication cost coverage        | Self-funded          | 77 (81.9)  | 17 (18.1) | 3.4 (2.04 to 6.62) | 2.05 (1.34 to 4.73) |
|                                 | Health insurance/free of charge | 176 (57.1) | 132 (42.9) | 1 | 1 |
| Number of medication            | ≥Triple therapy       | 70 (76.1)  | 22 (23.9) | 3.18 (1.82 to 8.69) | 2.34 (0.95 to 5.56) |
|                                 | Dual therapy         | 106 (67.9) | 50 (32.1) | 2.12 (1.56 to 7.56) | 1.27 (0.79 to 4.03) |
|                                 | Monotherapy          | 77 (50)    | 77 (50)   | 1              | 1 |
| Knowledge of hypertension and its treatment | Poor | 137 (77.4) | 40 (22.6) | 3.22 (1.67 to 4.95)** | 2.67 (1.45 to 3.99)* |
|                                 | Good                 | 116 (51.6) | 109 (48.4) | 1              | 1 |
| Patient–physician relationship  | Poor                 | 38 (73.1)  | 14 (26.9) | 1.56 (1.24 to 6.56) | 1.22 (1.02 to 4.34) |
|                                 | Good                 | 222 (63.4) | 128 (36.6) | 1              | 1 |
| Unavailability of medication during the COVID-19 pandemic | Yes | 196 (80) | 49 (20) | 7.02 (3.04 to 14.78)** | 5.05 (2.78 to 12.04)** |
|                                 | No                   | 57 (36.3)  | 100 (63.7) | 1              | 1 |
| Disturbed follow-up visits during the COVID-19 pandemic | Yes | 187 (69.5) | 82 (30.5) | 1.93 (1.13 to 4.71) | 1.32 (0.6 to 3.45) |
|                                 | No                   | 72 (54.1)  | 61 (45.9) | 1              | 1 |

*p<0.05, **p<0.001; 1=Reference. AOR, adjusted OR; COR, crude OR.
and Northwest Ethiopia. This could be due to a positive patient–physician interaction, would foster a pleasant therapeutic environment in which patients would have faith in healthcare professionals that enhance medication adherence.

Unavailability of antihypertensive medication during the COVID-19 pandemic showed correlation with poor antihypertensive medication adherence. This was congruent with previous studies conducted in the Democratic Republic of Congo and Ghozzi in Tunisia. This might be because patients who could not access antihypertensive medication easily in healthcare facilities or pharmacies, the risk of poor adherence would be apparent.

Strengths and limitations of the study

This study had several strengths. Firstly, the study used both primary and secondary data, which improves the accuracy of the data. Secondly, this study was a multicenter study, which increases the generalisability of its findings. Thirdly, this study was the first study that showed the impact of the COVID-19 pandemic on antihypertensive medication adherence in Eastern Ethiopia. Lastly, this finding showed the role of the patient–physician relationship in medication adherence. The possible limitation of this study was overestimation of the level of medication adherence since the data was collected by self-reporting.

CONCLUSION

The level of poor adherence to antihypertensive medication was high in this study. No formal education, comorbidity, self-sponsored medication cost coverage, poor knowledge about HTN and its treatment, poor patient–physician relationship and unavailability of medication during the COVID-19 pandemic were significantly associated with poor adherence to antihypertensive medication. All stakeholders should have strategies that reduce the impact of the COVID-19 or other pandemic on chronic diseases.

Acknowledgements

We acknowledge Haramaya University College of Health and Medical science for giving us the chance to conduct this study. Also, we would like to recognise all hospital administration and team.

Contributors

LA and SL contributed to the conception, study design, interpretation, and write-up; AW contributed to data collection for analysis and write-up of the draft and final manuscript. AA, HH, AS, YD, BN, and GMA oversee the data collection process and overall research work including interpretation of results, reviewing and revising critically the manuscript. All authors read and approved the final version to be submitted for publication.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Patient and public involvement

Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication

Consent obtained directly from patient(s).

Ethics approval

This study involves human participants and was approved by the Institutional Health, Research Ethics Review Committee of College of Health and Medical Sciences, Haramaya University (reference number HREC/227/2021). First, a supportive letter was written to the hospital’s administration from Haramaya University. Then, permission was obtained from each hospital’s administration. Participants in the study gave their written consent before data were collected. Throughout the research, data confidentiality was maintained. Furthermore, this study included no intrusive procedures and was carried out according to the Helsinki Declaration. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data are available upon reasonable request.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commerially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Lemessa Abdisa http://orcid.org/0000-0002-6912-1025

REFERENCES

1 Mendis S, O’Brien E, Seedat YK. Hypertension and diabetes: entry points for prevention and control of the global cardiovascular epidemic. Hindawi, 2013.
2 van de Vijver S, Akinyi H, Oti S, et al. Status report on hypertension in Africa—consultative review for the 6th Session of the African Union Conference of Ministers of Health on NCD’s. Pan Afr Med J 2013;16:38.
3 Kibret KT, Mesfin YM. Prevalence of hypertension in Ethiopia: a systematic meta-analysis. Public Health Rev 2015;36:14.
4 Gosmanova EO, Kovesdy CP. Adherence to antihypertensive medications: is prescribing the right pill enough? Nephrol Dial Transplant 2015;30:1649–56.
5 Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task force document. Blood Press 2009;18:308–47.
6 Matsumura K, Arima H, Tominaga M, et al. Impact of antihypertensive medication adherence on blood pressure control in hypertension: the comfort study. JMJ 2013;106:909–14.
7 Shin S, Song H, Oh S-K, et al. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res 2013;36:1000–5.
8 Kretchy JA, Asie Dano S, Kretchy J-P. Medication management and adherence during the COVID-19 pandemic: perspectives and experiences from low-and middle-income countries. Res Soc Adm Pharm 2021;17:2023–6.
9 Ivanova V, Pavlov D, Assenova T, et al. COVID-19 pandemic impact on the pharmaceutical sector in Bulgaria. PHAR 2021;68:713–20.
10 WHO. COVID-19 significantly impacts health services for non-communicable diseases, 2020.
11 Shimels T, Asrat Kassu R, Bogale G, et al. Magnitude and associated factors of poor medication adherence among diabetic and hypertensive patients visiting public health facilities in Ethiopia during the COVID-19 pandemic. PLoS One 2021;16:e0249222.
12 Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012;157:785–95.
13 Dego TR, Mulisa E. Adherence to anti-hypertensive medication and contributing factors among non-comorbid hypertensive patients in two hospitals of Jimma town, Southwest Ethiopia. Gullhane Medical Journal 2016;58:060–6.
14 Thompson K, Kularkan J, Sergejew AA. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. Schizophren Res 2000;42:241–7.
15 Erkoc SB, Işık B, Metintas S, et al. Hypertension Knowledge-Level scale (HK-LS): a study on development, validity and reliability. Int J Environ Res Public Health 2012;9:1018–29.
Open access

16. Zenger M, Schaefer T, van der Feltz-Cornelis C, et al. Validation of the Patient-Doctor-Relationship questionnaire (PDRQ-9) in a representative cross-sectional German population survey. PLoS One 2014;9:e91964.

17. Otenyo SO, Kikeri DK. Beliefs about Medicine and Antihypertensive Medication Adherence among Patients' Attending a County Referral Hospital in Kenya. European Journal of Clinical Medicine 2021;2:46–50.

19. Hussein A, Awad MS, Mahmoud HEM. Patient adherence to antihypertensive medications in upper Egypt: a cross-sectional study. Egypt Heart J 2020;72:1–8.

20. Fernández-Arias M, Acuna-Villardon A, Miranda JJ, et al. Adherence to pharmacotherapy and medication-related beliefs in patients with hypertension in Lima, Peru. PLoS One 2014;9:e112875.

21. Lo SHS, Chau JPC, Woo J, et al. Adherence to antihypertensive medication in older adults with hypertension. J Cardiovasc Nurs 2016;31:296.

22. Andualem A, Liknaw T, Edmealem A, et al. Adherence to antihypertensive medications among adult hypertensive patients attending chronic follow-up units of Dessie referral Hospital, northeastern Ethiopia: a cross-sectional study. Medicine 2018;2018:1127.

23. Aegendom SW, Atsey TM, Desse TA. Antihypertensive medication adherence and associated factors among adult hypertensive patients at Jimma university specialized Hospital, Southwest Ethiopia. BMC Res Notes 2018;11:27.

24. Mekonnen HS, Gebrie MH, Eyasu KH, et al. Drug adherence for antihypertensive medications and its determinants among adult hypertensive patients attending in chronic clinics of referral hospitals in Northwest Ethiopia. BMC Pharmacol Toxicol 2017;18:27.

25. Tichafer A, Mengistu D, Bulto LN. Adherence to prescribed antihypertensive medications and associated factors for hypertensive patients attending chronic follow-up units of selected public hospitals in Addis Ababa, Ethiopia. Int J Health Sci 2017;11:47.

26. Wake AD, Tufi TS, Sime AT, et al. Nonadherence to self-care practices, antihypertensive medications, and associated factors among hypertensive patients in a follow-up clinic at Asella referral and teaching Hospital, Ethiopia: a cross-sectional study. Int J Hypertens 2021;2021:7359318.

27. Bekele K, Mamo M. Antihypertensive medication non-adherence and predictors among adult patients on follow-up, Ethiopia: prospective cross-sectional study. Eur J Clin Pharm 2020;22:70–9.

28. Hasen G, Abdo A. Medication adherence and associated factors in management of hypertension in Shashemene referral Hospital, Ethiopia. Journal of Hypertension and Management 2020;3.

29. Pan J, Wu L, Wang H, et al. Determinants of hypertension treatment adherence among a Chinese population using the therapeutic adherence scale for hypertensive patients. Medicine 2019;38:e16116.

30. Berisa HD, Dedofo MG. Non-Adherence related factors to antihypertensive medications among hypertensive patients on follow up at Nedjo General Hospital in West Ethiopia. Open Public Health J 2018;11:62–71.

31. Dego TR, Bobasa EM. Adherence to anti-hypertensive medication and contributing factors among non-comorbid hypertensive patients in two hospitals of jimma town, Southwest Ethiopia. Guhilane Tip Dergisi 2016;38:60.

32. Jin J, Sklar GE, Min Sen Oh V, et al. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag 2008;4:269.

33. Burkart PV, Sabaté E. Adherence to Long-Term therapies: evidence for action. J Nurs Scholarsh 2003:35:207.

34. Getenet A, Tesfa M, Fereeda A, et al. Determinants of adherence to antihypertensive medications among adult hypertensive patients on follow-up in Hawassa referral Hospital: a case-control study. JRSM Cardiovasc Dis 2019;8:04:201992758.

35. Kang CD, Tsang PPM, Li WTL, et al. Determinants of medication adherence and blood pressure control among hypertensive patients in Hong Kong: a cross-sectional study. Int J Cardiol 2015;182:250–7.

36. Yuen Z, Bin W, Weilin Q, et al. Effect of medication adherence on blood pressure control and risk factors for antihypertensive medication adherence. J Eval Clin Pract 2015;21:166–72.

37. Lulebo AM, Mutombo PB, Mapatano MA, et al. Predictors of non-adherence to antihypertensive medication in Kinshasa, Democratic Republic of Congo: a cross-sectional study. BMC Res Notes 2015;8:05:2015826.

38. Teshome DF, Bekele KB, Habbitu YA, et al. Medication adherence and its associated factors among hypertensive patients attending the Debre Tabor General Hospital, Northwest Ethiopia. Integr Blood Press Control 2017;10:1.

39. Osamor PE, O wormi BE. Factors associated with treatment compliance in hypertension in Southwest Nigeria. J Health Popul Nutr 2011;29:619.

40. Ghozzi H, Kassis M, Hakim A, et al, eds. Observance medicamenteuse chez un échantillon d’hypertendus dans la région de Stax (Tunisie). Annales de Cardiologie et d’Angéiologie. Elsevier, 2010.